Original Minai release
Highlights
According to data from Minenet, among China's physical pharmacies, the sales scale in February 2024 was only 42.3 billion yuan, a year-on-year decrease of 7.9%; In terms of the TOP20 treatment categories of traditional Chinese medicine, the sales of cold and cough medicines increased significantly year-on-year, and the sales of Chinese patent medicines for cerebrovascular diseases decreased significantly.
Overall analysis of brick-and-mortar pharmacies: Affected by the Spring Festival holiday, the retail scale of brick-and-mortar pharmacies in China in February 2024 was 42.3 billion yuan, down 7.9% year-on-year
The 2024 Spring Festival holiday falls in mid-February, and some pharmacies are closed or have reduced their business hours, resulting in a corresponding decrease in customer flow. According to the latest data from the retail database of Minenet, the retail scale of China's physical pharmacies in February 2024 was 42.3 billion yuan, with sales down more than 20% from January and 7.9% from February 2023.
The cumulative retail scale from January to February 2024 was 96 billion yuan, a decrease of 6.3% from the same period last year, mainly due to the fact that sales were still relatively hot in the late stage of the new crown epidemic in January last year.
YTD：（Year to date）：表示从年初1月至当月的累计，下同
Market analysis of physical pharmacy categories: Affected by the Spring Festival holiday, drugs grew weakly year-on-year, and the remaining categories all had negative growth
As of February 2024, the share of pharmaceuticals has reached 82%, an increase of 0.6 percentage points from January 2023. In addition to medicines, the share of decoction pieces, devices, health products and other categories of products has decreased to varying degrees compared with the same period last year.
Judging from the cumulative sales growth rate from January to February 2024, only drugs have a positive growth of 2.1%, other categories of products have shown negative growth, the decline in devices is larger, down 45% year-on-year, the decline in health care products is also close to 40%, and the decline in traditional Chinese medicine decoction pieces is relatively small, about 13%.
In February 2024, the retail scale of drugs in China's physical pharmacies was 34.7 billion yuan, a decrease of 20.7% from January 2024 and a decrease of 1.5% compared with the same period last year.
In February 2024, the retail scale of traditional Chinese medicine decoction pieces in physical pharmacies nationwide was only 2.9 billion yuan, a decrease of nearly one-third from the previous month, and a year-on-year decline of 24.2%.
In February 2024, the retail scale of medical devices in physical pharmacies nationwide was 2 billion yuan, a decrease of 15.7% compared with January this year, which was the category with the smallest decline, and a decrease of 30.8% compared with the same period last year.
In February 2024, the retail scale of health care products in physical pharmacies nationwide was 1.7 billion yuan, a decrease of 500 million yuan from the previous month, a decrease of 20% month-on-month, and a large decline compared with the same period last year, with a year-on-year decline of nearly 40%.
Analysis of the TOP20 categories of Chinese medicine: the year-on-year sales of cold and cough medicines increased significantly, and the sales of cerebrovascular diseases Chinese patent medicines decreased significantly
In February 2024, the share of the top 20 chemical drug categories was about 80%, down 0.8 percentage points from 81.2% in the previous month, and the market size decreased by 4.3%, but increased by 11.7% year-on-year.
In addition, mineral supplements, urological drugs, ophthalmic drugs, sex hormones and reproductive system regulators have all risen, while diabetes drugs, systemic antiviral drugs, drugs for the treatment of gastric acid secretion-related diseases, antithrombotic drugs, and obstructive tracheal diseases have all declined.
Compared with the same period last year, the scale of systemic antibacterial drugs, cough and cold drugs, obstructive tracheal diseases and other categories has increased by different degrees, which is related to the low base of related drugs in the same period last year, as of February this year, the sales of the above categories of drugs have returned to normal levels.
In February 2024, the share of the TOP20 categories of Chinese patent medicine was 86.4%, which was basically the same as that of the previous month, but the sales scale decreased by 33.6% from the previous month, which was larger than that of chemical drugs.
Compared with January this year, pediatric cough and expectorant drugs and pediatric cold drugs fell out of the TOP20 categories in February, while intestinal drugs and heatstroke agents were on the list;
Compared with the same period last year, the categories with positive sales growth are: cough and expectorant and asthma drugs, cold drugs, heat clearing and detoxification drugs and throat drugs, all of which are related to the low sales of the above categories of drugs in the same period last year, which are related to the low sales level of the above categories of drugs after the new crown epidemic hoarding in the same period last year, and the categories with a large decline are: cerebrovascular disease drugs, neurological and cerebral tonic drugs and intestinal drugs, all of which decreased by more than 30%.
Data source: Minenet database